Bicara Therapeutics Inc., a company dedicated to innovative therapies, made public its intent to furnish a corporate presentation on January 13, 2025. The presentation, as detailed in its Form 8-K ...
In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...
Bicara Therapeutics (BCAX) announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback